S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Acceleron Pharma Stock Forecast, Price & News

+7.81 (+4.89 %)
(As of 09/24/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.23 million shs
Average Volume327,454 shs
Market Capitalization$10.21 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

Acceleron Pharma logo

About Acceleron Pharma

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

669th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

105th out of 193 stocks

Analyst Opinion: 1.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

Is Acceleron Pharma a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Acceleron Pharma stock.
View analyst ratings for Acceleron Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Acceleron Pharma?

Wall Street analysts have given Acceleron Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acceleron Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Acceleron Pharma

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.18. Acceleron Pharma had a negative net margin of 221.15% and a negative trailing twelve-month return on equity of 26.79%.
View Acceleron Pharma's earnings history

How has Acceleron Pharma's stock price been impacted by Coronavirus?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XLRN stock has increased by 98.7% and is now trading at $167.65.
View which stocks have been most impacted by COVID-19

What price target have analysts set for XLRN?

11 Wall Street analysts have issued 1-year price objectives for Acceleron Pharma's shares. Their forecasts range from $132.00 to $183.00. On average, they expect Acceleron Pharma's stock price to reach $156.00 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts' price targets for Acceleron Pharma
or view top-rated stocks among Wall Street analysts.

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:
  • Habib J. Dable, President, Chief Executive Officer & Director
  • Lisa Wyman, Vice President-Operations
  • Kevin F. McLaughlin, Chief Financial Officer, Treasurer & Senior VP
  • Ravindra Kumar, Chief Scientific Officer & Senior Vice President
  • Jay T. Backstrom, Executive VP & Head-Research & Development

What is Habib Dable's approval rating as Acceleron Pharma's CEO?

11 employees have rated Acceleron Pharma CEO Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among Acceleron Pharma's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.70%), Vanguard Group Inc. (8.06%), BlackRock Inc. (7.25%), FMR LLC (4.60%), Bamco Inc. NY (2.14%) and State Street Corp (1.82%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, Terrence C Kearney and Thomas A Mccourt.
View institutional ownership trends for Acceleron Pharma

Which institutional investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Goldman Sachs Group Inc., Vanguard Group Inc., TimesSquare Capital Management LLC, Invesco Ltd., Frontier Capital Management Co. LLC, and First Trust Advisors LP. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, Terrence C Kearney, and Thomas A Mccourt.
View insider buying and selling activity for Acceleron Pharma
or view top insider-selling stocks.

Which institutional investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Carmignac Gestion, Perceptive Advisors LLC, Perceptive Advisors LLC, Bank of Montreal Can, Bamco Inc. NY, State Street Corp, and Russell Investments Group Ltd..
View insider buying and selling activity for Acceleron Pharma
or or view top insider-buying stocks.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $167.65.

How much money does Acceleron Pharma make?

Acceleron Pharma has a market capitalization of $10.21 billion and generates $92.52 million in revenue each year. The biopharmaceutical company earns $-166,030,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Acceleron Pharma have?

Acceleron Pharma employs 312 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is www.acceleronpharma.com.

Where are Acceleron Pharma's headquarters?

Acceleron Pharma is headquartered at 128 SYDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at (617) 649-9200 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.